Wyss Institute at Harvard University’s Post

"In designing the eLBP, we tapped into the synthetic biology took kit that we have advanced over the past two decades and enabled Lactococcus lactis, a safe-to-use microbe, to secrete a β-lactamase enzyme that altruistically degrades β-lactams in the bacteria’s environment. The enzyme essentially becomes a ‘common good’ that cannot confer a selective advantage to the producing bacteria or be easily transferred to other bacteria, minimizing the risk and maximizing the clinical benefits of our approach." -Jim Collins #Dysbiosis #Microbiome #SyntheticBiology https://lnkd.in/gpg_RE9H

Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics

Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics

https://wyss.harvard.edu

To view or add a comment, sign in

Explore topics